Regeneron Pharmaceuticals, Inc.

REGNNASDAQHealthcare● Active

$635.45

+$6.72(+1.07%)

Market Cap$65.5B

P/E Ratio—

52W High$821.11

52W Low$476.49

Avg Volume831K

Open$632.26

Beta0.24

Free Cash Flow Financials Revenue

Regeneron Pharmaceuticals, Inc. (REGN) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

REGN · free cash flow · updated Jun 8, 2026

Core FCF metrics

REGN · FCF · TTM · margin & CAGR

Free cash flow was $4.08B for FY2025 (fiscal year ending 2025-12-31), up 11.3% year-over-year The FCF margin was 28.4%. Five-year CAGR stands at +15.3%.

FY2025 Free Cash Flow$4.08B▲ +11.3% YoY

Trailing 12M (TTM)$4.16Btrailing 4 quarters sum

FCF Margin28.4%$4.08B ÷ revenue

3-Year CAGR-2.7%FY2022 → FY2025

5-Year CAGR+15.3%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

REGN · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$4.98B(898M)$4.08B▲ +11.3%28.4%

FY2024$4.42B(756M)$3.66B▼ 0.1%25.8%

FY2023$4.59B(926M)$3.67B▼ 17.1%28.0%

FY2022$5.01B(590M)$4.42B▼ 32.2%36.4%

FY2021$7.08B(552M)$6.53B▲ +225.9%40.6%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

REGN · P/FCF · FCF yield · FCF per share

Regeneron Pharmaceuticals, Inc. (REGN) trades at a FCF yield of 6.35% and a price-to-free-cash-flow ratio of 16.0x. FCF per share stands at $39.72, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

6.35%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$39.72

TTM FCF ÷ Shares Outstanding

Price / FCF

x16.0

Share Price ÷ FCF per Share

EV / FCF (TTM)

x15.7

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

REGN · cash flow statement · operating / investing / financing

For FY2025, Regeneron Pharmaceuticals, Inc. generated $4.98B in operating cash flow and spent 898M in capital expenditures, yielding $4.08B in free cash flow.

Operating Activities

+$4.98B

Cash from core business operations

2025-12-31

Investing Activities

−$629.1M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$3.72B

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($4.98B) − |CapEx| (898M) = FCF ($4.08B)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

REGN vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Regeneron Pharmaceuticals, Inc.YOU

REGN

$4.08B+11.3%28.4%

21%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Regeneron Pharmaceuticals, Inc. (REGN) reported free cash flow of $4.08B for FY2025 (fiscal year ending 2025-12-31), up 11.3% year-over-year. The FCF margin was 28.4%.

Based on available data, Regeneron Pharmaceuticals, Inc. has maintained positive free cash flow for at least 13 fiscal year(s). FCF peaked at $6.53B in FY2021. The 5-year CAGR stands at +15.3%.

Regeneron Pharmaceuticals, Inc.'s FCF yield is 6.35% and price-to-FCF ratio is 16.0x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

REGN free cash flow · 8 questions

Regeneron Pharmaceuticals, Inc. free cash flow was $4.08B for FY2025, up 11.3% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $4.16B.

REGN free cash flowREGN FCFREGN FCF 2025REGN free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Regeneron Pharmaceuticals, Inc. · Regeneron Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026